Diopsys portable device aids in detection of retinal pathologies


Diopsys Inc. introduced a tabletop version of its electroretinography (ERG) and visual evoked potential (VEP) testing technology (ARGOS).

Las Vegas-Diopsys Inc. introduced a tabletop version of its electroretinography (ERG) and visual evoked potential (VEP) testing technology (ARGOS).

The device provides eye-care professionals (ECPs) with the same visual electrophysiology suite available in the company’s NOVA cart system, but in a tabletop version.

The company also announced a national rollout of its full-field electroretinography (ffERG) testing protocols, which will be available on both the ARGOS and NOVA systems. Previously only available in beta test sites, the ffERG tests use a handheld, mini-Ganzfeld dome to stimulate retinal cells.


The ffERG results may be used to indicate the level of functional loss on patients with maculopathies, and give ECPs the ability to measure the affect of maculopathies on vision through the presence of cataracts. The goal is to help ECPs better manage the patient and potential for IOL procedures.

“The launch of the [ARGOS] and the wider availability of full-field electroretinography testing demonstrates our commitment to being the leader in offering sophisticated yet versatile visual electrophysiology testing for the eye care professional,” said Joe Fontanetta, president and chief executive officer of Diopsys.

“ERG and VEP were typically reserved for laboratory and academic settings," Fontanetta said. "With the Diopsys NOVA system, and now ARGOS, eye-care specialists have the tools they need to perform objective, functional testing, which provides important information to help in early detection and better patient management.”




Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.